Pancreatic cancer is one of the most difficult cancers to detect early. Symptoms can be vague or absent until the disease has progressed, and there is currently no broadly recommended screening test for people at average risk.
The consequences are significant. The five-year relative survival rate for pancreatic cancer is less than 15%. When the disease is detected while still confined to the pancreas, that figure rises to approximately 44%.1
These numbers underscore why earlier detection matters. They also raise an important question: What can we learn about pancreatic cancer risk before symptoms appear?
At Radence, our approach to pancreatic cancer early detection begins with a more complete understanding of individual risk. Advanced imaging, whole-genome sequencing, metabolic testing, and family history each provide important information. Our physicians bring these findings together, drawing on continuously evaluated scientific evidence to determine what warrants closer investigation, what can be monitored, and when intervention may be appropriate.
This matters because the significance of a finding is rarely determined by a single test. A small pancreatic cyst, a change in blood sugar, or an inherited genetic variant may take on greater meaning when considered alongside the rest of a person's health information.
Sometimes the First Clue Is Found on an MRI
One of the important advantages of comprehensive imaging is the ability to identify unexpected abnormalities in people who have no symptoms. Radence's BioAtlas whole-body MRI can provide an opportunity to detect incidental findings that might otherwise remain undiscovered.
One example is an intraductal papillary mucinous neoplasm, or IPMN, a type of cyst that develops within the ducts of the pancreas.
IPMNs are increasingly discovered incidentally during MRI and CT scans, often in people who have no symptoms. Most never develop into cancer. However, some have characteristics that make them more concerning, including their size, growth rate, internal structure, and involvement of the main pancreatic duct.
Identifying an IPMN through imaging can bring a previously unknown finding to clinical attention, creating an opportunity for further evaluation before symptoms or complications develop.
There is another reason these findings deserve attention. Research suggests that people with IPMNs can have an increased risk of developing pancreatic cancer elsewhere in the pancreas, even when the original cyst remains stable.
This distinction has important implications for how pancreatic findings are evaluated and monitored over time.
"An IPMN may appear to be a small, isolated finding, but it can tell us something important about risk throughout the pancreas," states Brian Anhalt, Director of Clinical Implementation at Radence. "We look beyond the cyst itself to understand what it means for the individual and how that risk should be monitored over time."
Understanding Risk Requires More Than Imaging
Imaging provides essential information about the pancreas, but it is only one part of a comprehensive evaluation.
At Radence, when an IPMN is identified, our clinical team assesses the finding in the context of the member's broader health profile. This includes several sources of information:
- Advanced imaging: Our BioAtlas whole-body MRI protocol may identify an incidental pancreatic finding. Dedicated pancreatic MRI, including MRCP, can then provide a more detailed view of the lesion and pancreatic ducts when indicated.
- Genetic risk: Whole-genome sequencing can identify inherited variants associated with increased pancreatic cancer risk, including certain BRCA-related mutations.
- Family and medical history: A family history of pancreatic cancer, previous pancreatic conditions, and other established risk factors help inform the evaluation.
- Metabolic health: Changes in blood sugar regulation, particularly new-onset diabetes after age 50, can sometimes signal an increased risk of pancreatic cancer.
That last connection is especially important.
Research has shown that new-onset diabetes in adults over 50 can precede a pancreatic cancer diagnosis. While the vast majority of people who develop diabetes do not have pancreatic cancer, the change may warrant closer investigation in someone with additional risk factors.2
Radence evaluates metabolic health through testing that includes measures of insulin resistance, which may become abnormal before conventional blood sugar markers such as HbA1c.
By considering these findings together, our physicians can recognize changes that may alter an individual's risk assessment and determine whether additional pancreatic evaluation is appropriate.
Can a Blood Test Help Detect Pancreatic Cancer Earlier?
New blood-based technologies are expanding the possibilities for pancreatic cancer early detection. But incorporating an emerging test into clinical care requires more than promising performance data.
At Radence, our clinical protocols are informed by TechAtlas, the scientific research division of RA Capital, whose physicians and PhD scientists continuously evaluate emerging diagnostics, therapeutics, and biomedical evidence. This scientific foundation helps our physicians assess the strength of the evidence, understand the limitations of new technologies, and determine when they may meaningfully influence care.
One example is Avantect, a pancreas-focused blood test developed by ClearNote Health. It analyzes molecular changes in DNA fragments circulating in the bloodstream that may signal the presence of pancreatic cancer, including earlier-stage disease.
While early research is promising, additional studies are needed to establish its effectiveness in real-world screening and its impact on clinical outcomes.
Radence considers Avantect selectively for members whose risk factors and clinical circumstances make the additional information potentially useful. For example, a member over age 50 who develops new-onset diabetes, particularly alongside an IPMN, inherited susceptibility, or family history of pancreatic cancer, may warrant consideration.
Importantly, Avantect does not replace pancreatic imaging or establish a cancer diagnosis on its own. A positive result may prompt additional imaging or specialist evaluation, while a negative result does not eliminate the need for appropriate surveillance.
"The question we ask about any new diagnostic technology is whether the information will change what we do for a member. A promising test is only useful if we understand its limitations and have a clear plan for acting on the results," explains Brian Anhalt, Director of Clinical Implementation at Radence.
Why Continued Surveillance Matters
An IPMN that remains unchanged for several years may be reassuring. But stability does not necessarily mean that future pancreatic cancer risk has disappeared.
Current clinical guidelines allow surveillance to be discontinued in certain patients with small, stable branch-duct IPMNs after five years. However, long-term studies have demonstrated that pancreatic cancer can still develop beyond that period.
Radence takes a more cautious approach, favoring continued surveillance when clinically appropriate and when a member could benefit from intervention if a concerning change were detected.
The frequency and type of follow-up depend on the individual's risk profile, including imaging findings, genetic predisposition, metabolic changes, and other clinical considerations.
We also work with pancreatic specialists to evaluate findings and determine when additional testing, such as endoscopic ultrasound or molecular analysis of cyst fluid, may help clarify risk.
The objective is to detect meaningful changes while avoiding unnecessary procedures. Most pancreatic cysts will never become cancerous, and more aggressive testing can carry real consequences, including false-positive results, anxiety, and potentially avoidable interventions.
Knowing when to investigate further is as important as knowing when continued observation is the appropriate course.
Earlier Insight. Informed Decisions. Continued Attention.
The science of pancreatic cancer early detection continues to evolve, creating new opportunities to recognize risk and investigate concerning changes before symptoms develop.
At Radence, our clinical team draws on advanced diagnostics, rigorous scientific evaluation, and collaboration with leading specialists to understand what those findings mean for each member. As new information emerges, we revisit risk, refine surveillance plans, and determine when further action is warranted.
A pancreatic cyst discovered today may remain stable for years. Or changes in imaging, metabolic health, or other clinical findings may call for a closer look. What matters is having a physician-led team that understands the full picture and stays engaged as it evolves.
Because finding something early only creates an opportunity. Knowing what to do next is what makes that opportunity meaningful.
References
[1] National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. Surveillance, Epidemiology, and End Results (SEER) Program. Survival statistics based on 2016–2022 data.
[2] Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology. 2018;155(3):730–739.e3.
A More Complete Understanding of Your Health
Radence brings together advanced diagnostics, scientific expertise, and ongoing physician-led care to help you understand your health risks and make informed decisions about what comes next.



